Roche enters weight loss and metabolic market with Carmot Therapeutics acquisition
Roche has completed its acquisition of Carmot Therapeutics, which includes Carmot’s R&D portfolio including all clinical and pre-clinical...
top of page
Browse by category
Search
Roche poised to enter anti-obesity medication market with agreement to acquire Carmot Therapeutics
Roche is poised to enter the lucrative anti-obesity medication market after entering into a definitive merger agreement to acquire Carmot...
Carmot begins Phase 2 trial of dual GLP-1/GIP RA CT-868 for the treatment of type 1 diabetes
Carmot Therapeutics has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult...
Carmot’s CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes
Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for...
Browse by tag
bottom of page